Safety and Feasibility of Elective High-Risk Percutaneous Coronary Intervention Procedures With Left Ventricular Support of the Impella Recover LP 2.5

doi:10.1016/j.amjcard.2005.10.037

The American Journal of Cardiology

Volume 97, Issue 7, 1 April 2006, Pages 990-992

https://doi.org/10.1016/j.amjcard.2005.10.037 Get rights and content

Currently, the most used left ventricular (LV) support device is intra-aortic balloon counterpulsation. The percutaneous implantable Impella Recover LP 2.5 system is a novel LV (unloading) assist device. We studied the feasibility and safety of LV support with the percutaneous implantable Impella Recover LP 2.5 system in 19 consecutive high-risk patients with percutaneous coronary intervention. Procedural success using the device and percutaneous coronary intervention was achieved in all 19 patients, who were very poor candidates for surgery. The patients were elderly (84% were >60 years of age), 74% had previous myocardial infarction, 63% had LV ejection fractions of ≤25%, and all had LV ejection fractions of ≤40%. There were no procedural deaths and 2 device-unrelated in-hospital late deaths. Mean decrease in hemoglobin level was 0.7 ± 0.4 mmol/L. The device did not induce or increase aortic valve regurgitation. There were no important device-related adverse events during LV support with the Impella Recover LP 2.5 system. However, these encouraging findings must be confirmed by larger studies, longer assist times, and in other patient categories.

Section snippets

Acknowledgment

This work would not have been possible without the joined effort of the catheterization nurses, especially Sandra A. van Gilst and Wouter R. Rozendaal, clinical perfusionists, and cardiothoracic surgeons. We thank all echocardiographers who interrupted their normal duties to make echocardiograms before and during these procedures. We also thank our research department, especially Karla J.J. Mulder and F. Wilma van der Wateren, for data management.

References (11)

G.W. Stone et al.
A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplastySecond Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial Investigators
J Am Coll Cardiol
(1997)
C. Briguori et al.
Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplasty
Am Heart J
(2003)
M.P. Siegenthaler et al.
The Impella Recover microaxial left ventricular assist device reduces mortality for postcardiotomy failurea three-center experience
J Thorac Cardiovasc Surg
(2004)
A. Garatti et al.
Different applications for left ventricular mechanical support with the Impella Recover 100 microaxial blood pump
J Heart Lung Transplant
(2005)
A.W. van ’t Hof et al.
A randomized comparison of intra-aortic balloon pumping after primary coronary angioplasty in high risk patients with acute myocardial infarction
Eur Heart J
(1999)

There are more references available in the full text version of this article.

Cited by (196)

Predictors of Adverse Outcome in High-Risk Percutaneous Coronary Interventions Patients
2023, Canadian Journal of Cardiology
Identifying high-risk percutaneous coronary intervention (PCI) patients is challenging. We aimed to evaluate which high-risk patients are prone to adverse events.
We performed a retrospective study including consecutive high-risk PCIs from 2005 to 2018 in a large tertiary medical centre. Patients with unprotected left main (LM) disease, last patent coronary vessel, or 3-vessel coronary artery disease with left ventricular ejection fraction < 35% were included. A predictive 30-day major adverse cardiac events (MACE) score consisting of any myocardial infarction, all-cause death, or target-vessel revascularisation was constructed.
From 2005 to 2018, a total of 1890 patients who underwent PCI met the predefined high-risk PCI criteria. Mortality rate was 8.8% at 30 days and 20.7% at 1 year, and 30-day MACE rate was 14.2% and 33.5% at 1 year. Predictors of short-term MACE were New York Heart Association functional class (NYHA) 4 (hazard ratio [HR] 6.65; P < 0.001), systolic blood pressure (SBP) < 90 mm Hg (HR 4.93; P < 0.001), creatinine > 1.3 mg/dL (HR 3.57; P < 0.001), hemoglobin < 11.0 g/dL (HR 3.07; P < 0.001), pulmonary artery systolic pressure > 50 mm Hg (HR 2.06; P < 0.001), atrial fibrillation (HR 1.74; P < 0.001), and LM disease (HR 2.04; P < 0.001) or last patent vessel (HR 1.70; P = 0.002). A score constructed from these parameters reached a sensitivity of 90% and a specificity of 81% with areas under the receiver operating characteristic curve of 0.92 for MACE and 0.94 with 89% sensitivity and 87% specificity for all-cause mortality.
Specific features such as LM lesion or last patent conduit, pulmonary hypertension, atrial fibrillation, anemia, and renal failure, along with low SBP and NYHA 4, aid risk stratification and consideration of further treatment measures.
Contexte : Il s’avère difficile de cerner les interventions coronariennes percutanées (ICP) associées à un risque élevé. Notre objectif était donc d’évaluer quels patients sont susceptibles de subir des événements indésirables après une ICP.
Nous avons réalisé une étude rétrospective incluant des ICP consécutives associées à un risque élevé et réalisées entre 2005 et 2018 dans un grand centre médical tertiaire. Les patients présentant une sténose du tronc commun non protégé de l’artère coronaire gauche, une lésion touchant le dernier vaisseau coronaire perméable ou une maladie coronarienne tritronculaire avec fraction d’éjection ventriculaire gauche < 35 % ont été inclus. Un score prédictif d’événements cardiovasculaires indésirables majeurs (ECIM) à 30 jours comprenant l’infarctus du myocarde, le décès toutes causes confondues ou la revascularisation du vaisseau cible a été établi.
De 2005 à 2018, un nombre total de 1 890 patients ayant subi une ICP répondaient aux critères prédéfinis d’ICP associée à un risque élevé. Le taux de mortalité était de 8,8 % à 30 jours et de 20,7 % à 1 an, et le taux d’ECIM était de 14,2 % à 30 jours et de 33,5 % à 1 an. Les facteurs permettant de prédire la survenue d’ECIM à court terme étaient la classe fonctionnelle 4 de la New York Heart Association (NYHA) (rapport des risques instantanés [RRI] : 6,65; P < 0,001), une pression artérielle systolique (PAS) < 90 mmHg (RRI : 4,93; P < 0,001), un taux de créatinine > 1,3 mg/dL (RRI : 3,57; P < 0,001), un taux d’hémoglobine < 11,0 g/dL (RRI : 3,07; P < 0,001), une pression artérielle pulmonaire systolique > 50 mmHg (RRI : 2,06; P < 0,001), la fibrillation auriculaire (RRI : 1,74; P < 0,001), la sténose du tronc commun de l’artère coronaire gauche (RRI : 2,04; P < 0,001) ou une lésion touchant le dernier vaisseau perméable (RRI : 1,70; P = 0,002). Le score établi à partir de ces paramètres a atteint une sensibilité de 90 % et une spécificité de 81 % avec une aire sous la courbe de la fonction d’efficacité du récepteur (ASC-ROC) de 0,92 pour les ECIM, ainsi qu’une sensibilité de 89 % et une spécificité de 87 % pour la mortalité toutes causes confondues avec une ASC-ROC de 0,94.
Des caractéristiques particulières, telles que la sténose du tronc commun de l’artère coronaire gauche ou une lésion touchant le dernier vaisseau perméable, l’hypertension pulmonaire, la fibrillation auriculaire, l’anémie et l’insuffisance rénale, ainsi qu’une faible PAS et la classe 4 de la NYHA, facilitent la stratification des risques et l’examen des mesures thérapeutiques supplémentaires à adopter.
Temporary Extracorporeal Femoro-Femoral Crossover Bypass to Treat Acute Limb Ischemia due to Occlusive Femoral Transaortic Microaxial Left Ventricular Assist Device – A Novel Technique and Case Series
2022, Annals of Vascular Surgery
The Impella transaortic microaxial left ventricular assist device (MLVAD) bears the risk of severe ipsilateral limb ischemia due to its percutaneous insertion through the common femoral artery (CFA). As long as the MLVAD is required for cardio - circulatory support, treatment options are limited. Therefore, we developed a temporary extracorporeal femoral - femoral crossover bypass to restore and maintain perfusion of the affected leg.
From October 2018, we treated all patients with severe limb ischemia due to the MLAVD with a femoral - femoral crossover bypass. For comparison, a consecutive cohort of patients undergoing placement of the MLAVD between January 2011 and October 2018 was identified. The primary outcome is the feasibility and safety of our percutaneously established extracorporeal femoral - femoral crossover bypass.
Between January 2011 and July 2019, 25 of 245 (10.3%) patients developed a severe ipsilateral limb ischemia following the MLVAD placement. Until October 2018, 20 patients were treated conventionally (C - cohort) and since October 2018, five (consecutive) patients have been treated by an extracorporeal femoral - femoral cross over bypass (BP - Cohort). Following the BP - procedure, an immediate improvement of the perfusion was seen in all patients. Limb salvage was documented in 100% of our patients and 30 - day mortality was 60% in both groups.
This is the first case series reporting on this novel technique. We demonstrated that the percutaneous creation of an extracorporeal crossover bypass is feasible, safe and effective and should therefore be promoted.
ECPella: Concept, Physiology and Clinical Applications
2022, Journal of Cardiothoracic and Vascular Anesthesia
Addition of Impella on top of venoarterial extracorporeal membrane oxygenation (VA-ECMO) has gained wide interest as it might portend improved outcomes in patients with cardiogenic shock. This has been consistently reported in retrospective propensity-matched studies, case series, and meta-analyses.
The pathophysiologic background is based on the mitigation of ECMO-related side effects and the additive benefit of myocardial unloading. In this perspective, thorough knowledge of these mechanisms is required to optimize the management of mechanical circulatory support with this approach and introduce best practices, as the interplay between the two devices and the implantation-explantation strategies are key for success.
Non-extracorporeal membrane oxygenation artificial circulatory support for postcardiotomy syndrome
2022, Cardiopulmonary Bypass: Advances in Extracorporeal Life Support
Mechanical circulatory support (MCS) is an increasingly important component of the therapeutic arsenal in the treatment of cardiac and cardiopulmonary failure, and its utilization allows surgeons to assist patients who cannot be weaned off from cardiopulmonary bypass. A plethora of MCS device options exist. To optimize the patient care, one must understand the advantages and disadvantages of each device and select the appropriate device for appropriate clinical indications to achieve the best outcomes while minimize the complications. This chapter will provide an overview of temporary MCS devices, including intraaortic balloon pump, Impella, TandemHeart, CentriMag, and durable ventricular assist devices. We will discuss their respective advantages as well as adverse events associated with each strategy.
Impella in Transport: Physiology, Mechanics, Complications, and Transport Considerations
2022, Air Medical Journal
Cardiogenic shock (CS) represents a spectrum of hemodynamic deficits in which the cardiac output is insufficient to provide adequate tissue perfusion. The Impella (Abiomed Inc, Danvers, MA) device, a contemporary percutaneous ventricular support, is most often indicated for classic, deteriorating, and extremis Society for Coronary Angiography and Intervention stages of CS, which describe CS that is not responsive to optimal medical management and conventional treatment measures. Impella devices are an evolving field of mechanical support that is used with increasing frequency. Critical care transport medicine crews are required to transport patient support by the Impella device with increasing frequency. It is important that critical care transport medicine crews are familiar with the Impella device and are able to troubleshoot complications that may arise in the transport environment. This article reviews many aspects of the Impella device critical to the transport of this complex patient population.
Mechanical Circulatory Support in High-Risk Percutaneous Coronary Intervention
2021, Interventional Cardiology Clinics

View all citing articles on Scopus

View full text

Coronary artery diseaseSafety and Feasibility of Elective High-Risk Percutaneous Coronary Intervention Procedures With Left Ventricular Support of the Impella Recover LP 2.5

Section snippets

Acknowledgment

J Am Coll Cardiol

Am Heart J

J Thorac Cardiovasc Surg

J Heart Lung Transplant

A randomized comparison of intra-aortic balloon pumping after primary coronary angioplasty in high risk patients with acute myocardial infarction

Eur Heart J

Coronary artery disease
Safety and Feasibility of Elective High-Risk Percutaneous Coronary Intervention Procedures With Left Ventricular Support of the Impella Recover LP 2.5